Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Uterine Cervical Neoplasms 2Rectal Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Melanoma 1Hemangiosarcoma 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Gemcitabine 2Docetaxel 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2spartalizumab 1peginterferon alfa-2a 1balstilimab 1RNA, Messenger 1Paclitaxel 1Ipilimumab 1Granulocyte Colony-Stimulating Factor 1Glutamine 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Hemangiosarcoma × balstilimab × Clear all
NCT04607200 2022-01-11

AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma

Agenus Inc.

Phase 2 Withdrawn
Sarcoma

Hemangiosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡